Easton Pharmaceuticals Competitors

Easton Pharmaceuticals (OTCMKTS:EAPH) and Abacus Health Products (OTCMKTS:ABAHF) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Valuation & Earnings

This table compares Easton Pharmaceuticals and Abacus Health Products' gross revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Easton Pharmaceuticals and Abacus Health Products, as provided by MarketBeat.

Profitability

This table compares Easton Pharmaceuticals and Abacus Health Products' net margins, return on equity and return on assets.

Acreage (OTCMKTS:ACRGF) and Easton Pharmaceuticals (OTCMKTS:EAPH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Valuation and Earnings

This table compares Acreage and Easton Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a summary of recent recommendations and price targets for Acreage and Easton Pharmaceuticals, as reported by MarketBeat.com.

Acreage presently has a consensus target price of $8.4333, suggesting a potential upside of 204.45%. Given Acreage's higher probable upside, research analysts plainly believe Acreage is more favorable than Easton Pharmaceuticals.

Profitability

This table compares Acreage and Easton Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Acreage beats Easton Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Applied Biosciences (OTCMKTS:APPB) and Easton Pharmaceuticals (OTCMKTS:EAPH) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.

Profitability

This table compares Applied Biosciences and Easton Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings for Applied Biosciences and Easton Pharmaceuticals, as provided by MarketBeat.com.

Valuation and Earnings

This table compares Applied Biosciences and Easton Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Ayr Strategies (OTCMKTS:AYRSF) and Easton Pharmaceuticals (OTCMKTS:EAPH) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Ayr Strategies and Easton Pharmaceuticals, as reported by MarketBeat.

Ayr Strategies presently has a consensus target price of $34.8571, indicating a potential upside of 63.96%. Given Ayr Strategies' higher probable upside, equities analysts clearly believe Ayr Strategies is more favorable than Easton Pharmaceuticals.

Valuation and Earnings

This table compares Ayr Strategies and Easton Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Ayr Strategies and Easton Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Ayr Strategies beats Easton Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Can B (NASDAQ:CANB) and Easton Pharmaceuticals (OTCMKTS:EAPH) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Profitability

This table compares Can B and Easton Pharmaceuticals' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Can B and Easton Pharmaceuticals' gross revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Can B and Easton Pharmaceuticals, as reported by MarketBeat.com.

Cansortium (OTCMKTS:CNTMF) and Easton Pharmaceuticals (OTCMKTS:EAPH) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Earnings & Valuation

This table compares Cansortium and Easton Pharmaceuticals' top-line revenue, earnings per share and valuation.

Profitability

This table compares Cansortium and Easton Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cansortium and Easton Pharmaceuticals, as provided by MarketBeat.com.

Cansortium presently has a consensus target price of $1.20, suggesting a potential upside of 43.13%. Given Cansortium's higher probable upside, analysts plainly believe Cansortium is more favorable than Easton Pharmaceuticals.

Summary

Cansortium beats Easton Pharmaceuticals on 2 of the 2 factors compared between the two stocks.